Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS
DOI:
https://doi.org/10.2340/actadv.v105.41298Keywords:
hidradenitis suppurativa, life quality, patient outcome assessment, patient-reported outcomesAbstract
Hidradenitis suppurativa is a chronic skin disease associated with significant disease burden. To assess patients’ treatment benefits, disease-specific outcomes measurement is needed. This study aimed to develop a questionnaire called Patient Benefit Index for hidradenitis suppurativa (PBI-HS). After an open-item survey, the items were condensed into a 26-item questionnaire on patient needs and benefits, with a 5-point Likert scale. In the validation study, construct and content validity, responsiveness, and feasibility of the questionnaire were assessed at 2 time points. A 26-item questionnaire was created following open-item generation by n = 72 patients. In the validation study, 3 items perceived as most relevant by patients were: “to be free of pain” (mean: 3.6 on a scale of 0–4), “to be free of inflammation” (mean: 3.6), “to have no more scars” (mean: 3.1). Significant correlations of PBI-HS at follow-up visit were found with the physical global assessment for hidradenitis suppurativa (HS-PGA) (r = –0.471; p = 0.000), number of inflammatory lesions (r = –0.359; p = 0.005), and DLQI (r = –0.383; p = 0.003), indicating less disease burden in patients with higher treatment benefits. The PBI-HS is a feasible and valid instrument to assess patient-reported treatment benefits in hidradenitis suppurativa.
Downloads
References
Frew JW, Lowes MA, Goldfarb N, Butt M, Piguet V, O'Brien E, et al. Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary. JAMA Dermatol 2021; 157: 449-455.
https://doi.org/10.1001/jamadermatol.2020.5467 DOI: https://doi.org/10.1001/jamadermatol.2020.5467
Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35: 191-194.
https://doi.org/10.1016/S0190-9622(96)90321-7 DOI: https://doi.org/10.1016/S0190-9622(96)90321-7
Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 69: 819.
https://doi.org/10.1016/j.jaad.2013.06.042 DOI: https://doi.org/10.1016/j.jaad.2013.06.042
Kirsten N, Zander N, Augustin M. Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 2021; 313: 95-99.
https://doi.org/10.1007/s00403-020-02065-2 DOI: https://doi.org/10.1007/s00403-020-02065-2
Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 2015; 173: 1546-1549.
https://doi.org/10.1111/bjd.14038 DOI: https://doi.org/10.1111/bjd.14038
Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GBE, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013; 27: 473-478.
https://doi.org/10.1111/j.1468-3083.2012.04468.x DOI: https://doi.org/10.1111/j.1468-3083.2012.04468.x
Matusiak Ł, Szczęch J, Kaaz K, Lelonek E, Szepietowski JC. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol 2018; 98: 191-194.
https://doi.org/10.2340/00015555-2815 DOI: https://doi.org/10.2340/00015555-2815
Alavi A, Farzanfar D, Lee RK, Almutairi D. The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J Cutan Med Surg 2018; 22: 166-174.
https://doi.org/10.1177/1203475417745826 DOI: https://doi.org/10.1177/1203475417745826
Frings VG, Bauer B, Glöditzsch M, Goebeler M, Presser D. Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol 2019; 29: 294-301.
https://doi.org/10.1684/ejd.2019.3552 DOI: https://doi.org/10.1684/ejd.2019.3552
Balieva F, Kupfer J, Lien L, Gieler U, Finlay AY, Tomás-Aragonés L, et al. The burden of com-mon skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries. Br J Dermatol 2017; 176: 1170-1178.
https://doi.org/10.1111/bjd.15280 DOI: https://doi.org/10.1111/bjd.15280
Zouboulis CC, Chernyshov PV. Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 2021; 35: 1420-1421.
https://doi.org/10.1111/jdv.17306 DOI: https://doi.org/10.1111/jdv.17306
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Nijsten TEC, Sampogna F, Chren M-M, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006; 126: 1244-1250.
https://doi.org/10.1038/sj.jid.5700212 DOI: https://doi.org/10.1038/sj.jid.5700212
McLellan C, Sisic M, Oon HH, Tan J. Preliminary Validation of the HS-QoL: A quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg 2018; 22: 142-146.
https://doi.org/10.1177/1203475417736281 DOI: https://doi.org/10.1177/1203475417736281
Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schäfer I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 2009; 301: 561-571.
https://doi.org/10.1007/s00403-009-0928-8 DOI: https://doi.org/10.1007/s00403-009-0928-8
Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 2012; 304: 433-441.
https://doi.org/10.1007/s00403-012-1256-y DOI: https://doi.org/10.1007/s00403-012-1256-y
Blome C, Radtke MA, Eissing L, Augustin M. Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016; 17: 163-169.
https://doi.org/10.1007/s40257-015-0171-3 DOI: https://doi.org/10.1007/s40257-015-0171-3
Augustin M, Blome C, Zschocke I, Schäfer I, Koenig S, Rustenbach SJ, et al. Benefit evaluation in the therapy of chronic wounds from the patients' perspective - development and validation of a new method. Wound Repair Regen 2012; 20: 8-14.
https://doi.org/10.1111/j.1524-475X.2011.00751.x DOI: https://doi.org/10.1111/j.1524-475X.2011.00751.x
Augustin M. Erfassung von Lebensqualität in dermatologischen Studien. Leitlinie der Subkommission "Pharmako-Okonomie und Lebensqualität". Hautarzt 2001; 52: 697-700.
https://doi.org/10.1007/s001050170083 DOI: https://doi.org/10.1007/s001050170083
Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846-855.
https://doi.org/10.7326/0003-4819-157-12-201212180-00004 DOI: https://doi.org/10.7326/0003-4819-157-12-201212180-00004
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20: 1727-1736.
https://doi.org/10.1007/s11136-011-9903-x DOI: https://doi.org/10.1007/s11136-011-9903-x
Šimkovic M, Träuble B. Robustness of statistical methods when measure is affected by ceiling and/or floor effect. PLoS One 2019; 14: e0220889.
https://doi.org/10.1371/journal.pone.0220889 DOI: https://doi.org/10.1371/journal.pone.0220889
Blome C, Maares J, Diepgen T, Jeffrustenbach S, Augustin M. Measurement of patient-relevant benefits in the treatment of chronic hand eczema - a novel approach. Contact Dermatitis 2009; 61: 39-45.
https://doi.org/10.1111/j.1600-0536.2009.01536.x DOI: https://doi.org/10.1111/j.1600-0536.2009.01536.x
Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I. Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire. Dermatology 2008; 217: 101-106.
https://doi.org/10.1159/000128992 DOI: https://doi.org/10.1159/000128992
Published
How to Cite
License
Copyright (c) 2025 Natalia Kirsten, Matthias Augustin, Christine Blome, Janine Topp, Richard Schwager, Falk G. Bechara, Gefion Girbig, Andreas Pinter, Florian Anzengruber, Mareen Lindegaard, Christos C. Zouboulis, Marina Otten
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
